Browse Category

Stock Market News 21 January 2026

Bank of America stock slips after $1B employee stock award as credit-card cap deadline bites

Bank of America stock slips after $1B employee stock award as credit-card cap deadline bites

Bank of America shares fell 1.64% to $52.10 Tuesday, then held steady after hours. The bank announced a $1 billion employee stock grant, totaling nearly 19 million shares. Investors weighed the move against uncertainty over a possible 10% federal cap on credit-card interest rates. CEO Brian Moynihan sold and repurchased about 17,900 shares last week, according to SEC filings.
3M stock price drops after outlook miss, with tariffs and 2026 demand back in focus

3M stock price drops after outlook miss, with tariffs and 2026 demand back in focus

3M shares fell about 7% to $156 in after-hours trading Tuesday after its 2026 profit forecast narrowly missed analyst estimates. The company reported fourth-quarter adjusted earnings of $1.83 per share, beating forecasts, but consumer segment sales dropped 1.2%. Management cited patchy demand and tariff risks. Investors await tariff updates before Feb. 1.
KLA stock sinks 5% in late-day slide; analysts lift targets ahead of Jan. 29 results

KLA stock sinks 5% in late-day slide; analysts lift targets ahead of Jan. 29 results

KLA shares fell 5.2% Tuesday to $1,486.18, underperforming chip-sector peers during a broad U.S. market selloff. Trading volume topped 1.7 million shares, above average. The drop comes days before KLA’s Jan. 29 earnings report, with analysts raising price targets despite the slide. The stock now sits about 6% below its Jan. 16 high.
Corvus Pharmaceuticals stock surges 167% on eczema drug data as $150 million offering kicks off

Corvus Pharmaceuticals stock surges 167% on eczema drug data as $150 million offering kicks off

Corvus Pharmaceuticals shares soared over 167% to $21.41 in after-hours trading Tuesday after reporting positive placebo-controlled trial results for its experimental eczema pill. The company launched a $150 million underwritten stock and warrant offering following the data release. Analysts raised price targets. About 84 million shares changed hands.
Lumentum stock jumps 10% as Aletheia lifts target to $500 ahead of Feb. 3 earnings

Lumentum stock jumps 10% as Aletheia lifts target to $500 ahead of Feb. 3 earnings

Lumentum shares rose about 10% Tuesday, closing at $356.83 and holding steady after hours. Aletheia Capital’s Skye Chen raised his price target to $500, citing stronger demand for high-speed data-center lasers. Lumentum reports fiscal Q2 results Feb. 3 after the market closes. The company will also present new laser platforms at SPIE Photonics West this week.
Applied Materials stock price dips despite Needham’s big target hike — here’s what traders watch next

Applied Materials stock price dips despite Needham’s big target hike — here’s what traders watch next

Applied Materials fell 2.7% to $318.23 Tuesday, mirroring a sharp drop in semiconductor stocks and the S&P 500. The decline came despite Needham raising its price target to $390, citing stronger demand. Shares traded between $314.58 and $324.35 on volume of 9.4 million. Investors await earnings from ASML and KLA next week, with Applied’s own report due Feb. 12.
RAPT Therapeutics stock jumps 64% as GSK agrees $2.2 billion takeover at $58 a share

RAPT Therapeutics stock jumps 64% as GSK agrees $2.2 billion takeover at $58 a share

Rapt Therapeutics shares surged 64% to $57.57 in after-hours trading after GSK agreed to acquire the company for $58 a share in cash, valuing Rapt at about $2.2 billion. The deal centers on ozureprubart, a long-acting anti-IgE antibody. GSK plans to launch a tender offer within 10 business days. Closing depends on a majority of Rapt shares being tendered and U.S. antitrust clearance.
AST SpaceMobile stock slips late as Deutsche Bank, Clear Street lift targets to $137

AST SpaceMobile stock slips late as Deutsche Bank, Clear Street lift targets to $137

AST SpaceMobile shares dropped 2.8% to $112.44 Tuesday after volatile trading. Deutsche Bank and Clear Street each raised their price targets to $137, maintaining Buy ratings. Investors are watching the company’s satellite launch schedule and legal developments as competition intensifies. About 18.4 million shares traded hands during the session.
Goldman Sachs stock drops after-hours as credit-card cap deadline hits banks; Qatar $25B tie-up in focus

Goldman Sachs stock drops after-hours as credit-card cap deadline hits banks; Qatar $25B tie-up in focus

Goldman Sachs shares fell 1.9% to $943.37 in after-hours trading Tuesday as investors awaited a White House decision on capping credit card interest rates. Bank stocks broadly declined, with JPMorgan down 3.1% and Citigroup off 4.4%. Goldman also announced a new deal with the Qatar Investment Authority to raise up to $25 billion for managed funds and co-investments. RBC Capital raised its price target on Goldman to $1,030.
Coinbase stock drops after hours as bitcoin slides; Armstrong keeps crypto bill push alive in Davos

Coinbase stock drops after hours as bitcoin slides; Armstrong keeps crypto bill push alive in Davos

Coinbase shares fell 5.5% to $227.73 in after-hours trading Tuesday after bitcoin dropped 4.6% to about $88,312. CEO Brian Armstrong, speaking in Davos, said he remains optimistic about U.S. crypto legislation despite recent setbacks. Bermuda announced plans for a fully onchain national economy using Circle and Coinbase infrastructure, drawing regulatory attention.
Lam Research stock swings on tariff jitters as UBS lifts target ahead of earnings

Lam Research stock swings on tariff jitters as UBS lifts target ahead of earnings

Lam Research shares closed down 0.25% Tuesday, holding near $222 in muted after-hours trading as tariff threats from President Trump pressured tech stocks. UBS raised its price target on Lam to $255, citing strong Q2 prospects. Lam’s earnings report is set for Jan. 28. Applied Materials and KLA fell more sharply, dropping 2.7% and 5.2% respectively.
Eli Lilly stock ticks up after FDA “breakthrough” tag for ovarian cancer drug

Eli Lilly stock ticks up after FDA “breakthrough” tag for ovarian cancer drug

Eli Lilly shares closed up 0.3% at $1,041.29 Tuesday and rose slightly after hours after the FDA granted Breakthrough Therapy status to its ovarian cancer drug candidate, sofetabart mipitecan. The designation targets adults with platinum-resistant ovarian cancer. Analyst Seamus Fernandez maintained a buy rating but trimmed his price target. Abivax’s CEO denied rumors of takeover talks with Lilly.

Stock Market Today

ST Engineering stock price drops 2% to S$9.71 as drone-autonomy tie-up grabs attention

ST Engineering stock price drops 2% to S$9.71 as drone-autonomy tie-up grabs attention

7 February 2026
ST Engineering shares fell 1.9% to S$9.71 Friday, outpacing the Singapore market’s 0.8% drop amid a tech-led selloff. The company signed a deal with Shield AI at the Singapore Airshow to integrate autonomy software into its unmanned platforms and unveiled a small drone capable of carrying explosives. About 6.9 million shares traded as investors await full-year results on Feb. 27.
Go toTop